Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter
TORONTO, ONTARIO--(Marketwired - Feb 9, 2018) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to …